Abstract 5010
Background
Although immunotherapy treatment (ImT) supposes a great advance for cancer patients, it also presents a challenge to health professionals, not only because of their adverse-event profile differs from chemotherapy or radiotherapy but, because it introduces new areas of clinical practice. All Immunotherapy Clinical Guidelines highlight the importance of prevent adverse effects related-IrAE, education and monitoring patients is crucial. In 2018 the Catalan Institute of Oncology (ICO), along with 4 European oncology institutions launched the VIKHI project, (Virtual International Knowledge Hub in Inmuno-Therapy) to improve care delivery, education of professionals and patients on receiving ImT through a comprehensive training program. Objective: cross-sectional study evaluating knowledge that patients have about their immunotherapy treatment.
Methods
From July 2018-March 2019, all patients treated with ImT first time were recruited non-probabilistic sample. They had to answer 10 questions about their knowledge on disease & treatment, and quality of life with EORTC-QLC30 scale. The interviews were conducted by clinical nurse specialist.
Results
A total of 85 patients. By tumors; lung 74.11%, head-neck 7.05%, melanoma 5.88%, renal 3.52% and double tumors 9.41%. They received ImT as part as their standard treatment in 62.35% and 37.64% as clinical trial and in 31.77% were their first treatment. 91.76% patients were knowledgeable about receiving ImT, but only 3.52% were not aware and 4.70% describe Chemo+ImT. About being able to identify complications, diarrhoea was the most described by 25.23%, followed by skin problems by 23.38%, thyroid problems and fever 13.53% and alopecia by 0.30%. Only two patients were unable to identify any. Informed by oncologist 63.5% and by nurses 32.9%. Only 7% of patients considered being fully informed.
Conclusions
Still room to improve about patient education and communication for patients receiving ImT. It would be important to train the HCP’s, especially nurses, so that they can effectively inform and educate patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Catalan Institute of Oncology.
Funding
Independent Educational Grant from Pfizer IGCL Grant ID: 34096003.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract